Inactive Instrument

Biodexa Pharmaceuticals Plc Stock price London S.E.

Equities

BDRX

GB00BNGF1L75

Biotechnology & Medical Research

Sales 2023 * 298K 379K Sales 2024 * - Capitalization 2.35M 2.99M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * 7.88 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * -
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 27
Yield 2023 *
-
Yield 2024 *
-
Free-Float 57.92%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5% MT
Biodexa Pharmaceuticals plc Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Wednesday Trading MT
ADRs Close Lower, Polestar Automotive Holding UK PLC Wt Declines 35.3% DJ
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
Top Premarket Gainers MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
Ladenburg Thalmann Starts Biodexa Pharmaceuticals With Buy Rating, $8 Price Target MT
More news
Managers TitleAgeSince
Chief Executive Officer 62 19-09-08
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 65 22-06-19
Director/Board Member 65 14-10-28
Chief Executive Officer 62 19-09-08
More insiders
Biodexa Pharmaceuticals PLC is a United Kingdom-based drug delivery technology company. The Company is focused on improving the bio-delivery and bio-distribution of medicines. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. Biodexa Pharmaceuticals Q-Sphera technology focuses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. It has a pipeline of approximately eight earlier stage programs, MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma), MTX110 (Glioblastoma), MTX114 (Psoriasis), MTD211 (Schizophrenia, MDD) and others.
More about the company
  1. Stock
  2. Equities
  3. Stock Biodexa Pharmaceuticals Plc
  4. Stock Biodexa Pharmaceuticals Plc - London S.E.